These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 15020609

  • 1. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM.
    J Clin Oncol; 2004 Mar 15; 22(6):1078-86. PubMed ID: 15020609
    [Abstract] [Full Text] [Related]

  • 2. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C.
    Leukemia; 2001 May 15; 15(5):764-71. PubMed ID: 11368437
    [Abstract] [Full Text] [Related]

  • 3. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
    Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL.
    Blood; 1999 Feb 01; 93(3):787-95. PubMed ID: 9920827
    [Abstract] [Full Text] [Related]

  • 4. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P.
    Adv Exp Med Biol; 1999 Feb 01; 457():47-56. PubMed ID: 10500779
    [Abstract] [Full Text] [Related]

  • 5. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM.
    Cancer; 1999 Jan 15; 85(2):358-67. PubMed ID: 10023703
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
    O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV.
    Pediatr Blood Cancer; 2010 May 15; 54(5):694-702. PubMed ID: 20209646
    [Abstract] [Full Text] [Related]

  • 8. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, Peaud PY, Martin C, Amadori S, Willemze R.
    Leukemia; 1999 Jun 15; 13(6):843-9. PubMed ID: 10360370
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
    Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR.
    Leuk Res; 2000 Jul 15; 24(7):567-74. PubMed ID: 10867130
    [Abstract] [Full Text] [Related]

  • 10. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K, Ohnishi K.
    Gan To Kagaku Ryoho; 2005 Mar 15; 32(3):292-6. PubMed ID: 15791811
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA, Children's Cancer Group Study 2951.
    J Clin Oncol; 2003 Aug 01; 21(15):2940-7. PubMed ID: 12885813
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
    Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D.
    J Clin Oncol; 2005 Jun 20; 23(18):4110-6. PubMed ID: 15961759
    [Abstract] [Full Text] [Related]

  • 16. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
    Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Milpied N, Janvier M, Guerci A, Rochant H, Cordonnier C, Dreyfus F, Veil A, Hoang-Ngoc L, Stoppa AM, Gratecos N, Sadoun A, Tilly H, Brice P, Lioure B, Desablens B, Pignon B, Abgrall JP, Leporrier M, Fenaux P.
    Adv Exp Med Biol; 1999 Jun 20; 457():35-46. PubMed ID: 10500778
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
    Vignetti M, Orsini E, Petti MC, Moleti ML, Andrizzi C, Pinto RM, Amadori S, Meloni G.
    Ann Oncol; 1996 Nov 20; 7(9):933-8. PubMed ID: 9006744
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.